ArticleWorld journal of gastroenterology2005
Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus.
Article in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- High serum superoxide dismutase activity improves radiation-related quality of life in patients with esophageal squamous cell carcinoma.Clinics (Sao Paulo, Brazil) · 2021Article
- From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.Biochimica et biophysica acta. Reviews on cancer · 2019Review
- Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases.Physiological reviews · 2014Review
- Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.World journal of gastroenterology · 2012Article
- Chemoprotective effects of curcumin in esophageal epithelial cells exposed to bile acids.World journal of gastroenterology · 2010Article
- Nrf2-Keap1 signaling as a potential target for chemoprevention of inflammation-associated carcinogenesis.Pharmaceutical research · 2010Review
- Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice.BMC gastroenterology · 2009Article
- Barrett's esophagus: where do we stand?Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2009Article
- Chemoprevention of esophageal adenocarcinoma.Therapeutic advances in gastroenterology · 2008Article
- Article
- Inflammation and oxidative stress in gastroesophageal reflux disease.Journal of clinical biochemistry and nutrition · 2007Article
- Barrett's esophagus: best of Digestive Disease Week 2003.Current gastroenterology reports · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo test whether antioxidant treatment could prevent the progression of Barrett's esophagus to adenocarcinoma.
methodsIn a rat model of gastroduodenoesophageal reflux by esophagojejunal anastomosis with gastric preservation, groups of 6-10 rats were randomized to receive treatment with superoxide dismutase (SOD) or vehicle and followed up for 4 mo. Rat's esophagus was assessed by histological analysis, superoxide anion and peroxinitrite generation, SOD levels and DNA oxidative damage.
resultsAll rats undergoing esophagojejunostomy developed extensive esophageal mucosal ulceration and inflammation by mo 4. The process was associated with a progressive presence of intestinal metaplasia beyond the anastomotic area (9% 1st mo and 50% 4th mo) (94% at the anastomotic level) and adenocarcinoma (11% 1st mo and 60% 4th mo). These changes were associated with superoxide anion and peroxinitrite mucosal generation, an early and significant increase of DNA oxidative damage and a significant decrease in SOD levels (P<0.05). Exogenous administration of SOD decreased mucosal superoxide levels, increased mucosal SOD levels and reduced the risk of developing intestinal metaplasia beyond the anastomotic area (odds ratio = 0.326; 95%CI: 0.108-0.981; P = 0.046), and esophageal adenocarcinoma (odds ratio = 0.243; 95%CI: 0.073-0.804; P = 0.021).
conclusionSuperoxide dismutase prevents the progression of esophagitis to Barrett's esophagus and adenocarcinoma in this rat model of gastrointestinal reflux, supporting a role of antioxidants in the chemoprevention of esophageal adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.